The maf oncogene of the avian oncogenic retrovirus AS42 encodes a nuclear bZip protein, v-Maf, that recognizes sequences related to the AP-1 target site. The corresponding cellular protein, c-Maf belongs to a family of related bZip proteins together with MafA and MafB. In this paper, we compare the transactivation and cell transforming abilities of MafA and MafB along with two forms of the c-Maf protein. These proteins induce cellular transformation when expressed in chicken embryo fibroblasts. In reporter assays, MafA is a much less effective transactivator than the other Maf proteins, but unexpectedly shows the strongest activity in cell transformation. Chimeras of MafA and MafB correlate the strong cell transforming ability of MafA with its DNA-binding domain. The DNA-binding domain of MafA is also correlated with weak transactivation. Additional mutagenesis experiments show that transactivation and transformation by MafA are also controlled by phosphorylation of two conserved serine residues in the transactivation domain. Finally, we constructed MafAestrogen receptor fusion molecules that show tightly hormone-dependent cell transforming ability. These regulatable constructs permit a kinetic characterization of target gene responses and facilitate discrimination between direct and indirect targets.
Introduction
The maf oncogene was identified in an acutely oncogenic avian retrovirus, AS42, isolated from a spontaneous chicken tumor (Nishizawa et al., 1989; Kawai et al., 1992) . It is the prototype of a family of six related genes that code for bZip proteins. This family encompasses three small and four large Maf proteins. The large Mafs, cellular and viral Maf (c-Maf, v-Maf) , MafA (also known as L-Maf) (Benkhelifa et al., 1998; Ogino and Yasuda, 1998) , MafB (Cordes and Barsh, 1994; Kataoka et al., 1994a) and NRL (Swaroop et al., 1992) contain a putative transactivation domain in their amino-terminal region. This region is well conserved and is rich in acidic amino acids. Deletion of this region of v-Maf reduces cell transforming and transactivation activities. A structure-function study of v-Maf supports the idea that Maf induces transformation by transcriptional deregulation of downstream target genes .
The cellular maf gene (c-maf) and mafB are rearranged and show gain of function in human tumors. In multiple myeloma, the c-maf locus is frequently translocated to either the immunoglobulin heavy or the light chain gene, and expression is elevated, probably through an enhancer effect (Chesi et al., 1998; Bergsagel and Kuehl, 2001) . Similarly, the related mafB shows elevated expression in multiple myelomas that also carry a chromosomal translocation (Hanamura et al., 2001) . The small Maf proteins, MafK (Fujiwara et al., 1993) , MafF (Fujiwara et al., 1993) and MafG (Kataoka et al., 1995) lack a transactivation domain. These proteins can interact with other bZip proteins to form heterodimers that transactivate (Andrews et al., 1993; Igarashi et al., 1994) , but they fail to induce oncogenic transformation on their own (Fujiwara et al., 1993) .
The bZip domain is located at the C-terminus of the Maf proteins. This well-conserved region determines DNA-binding and dimerization specificities. The Maf proteins recognize 13-or 14-base palindromic sequences that are related to the recognition sequence of AP-1 transcription factors (Kataoka et al., 1994b; Kerppola and Curran, 1994) . Since the Maf-recognition element (MARE) is relatively long, we have previously tried to find such elements in 5 0 -noncoding sequences of eukaryotic genes (Kataoka et al., 1994b) . Some of these MAREs were confirmed as Maf targets. For instance, genes for phase II enzymes, that are induced by Xenobiotics, are regulated by complexes that include a small Maf and another bZip factor, Nrf2 (Itoh et al., 1997) . c-Maf and Nrl regulate lens-and retina-specific gene expression (Kumar et al., 1996; Sharon-Friling et al., 1998; Kawauchi et al., 1999; Kim et al., 1999a, b; Ring et al., 2000) . Gene targeting of c-maf induces severe defects in the development of several tissues, including the eye. MafA is also a positive regulator of genes expressed in eye tissue, the retina-specific QR1 gene and crystalline genes (Benkhelifa et al., 1998 (Benkhelifa et al., , 2001 Ogino and Yasuda, 1998) . c-Maf is also important in the differentiation of CD4 þ T cells into Th1 and Th2 T cells (Ho et al., 1998; Kim et al., 1999a, b; Ho and Glimcher, 2002) . Recent results show that MafA is involved in glucose-regulated insulin gene expression in pancreatic b-cells (Olbrot et al., 2002; Kataoka et al., submitted) . Although several targets of the Maf family proteins have been identified, the mechanism of cell transformation by Maf remains unknown.
In this study, we compare transactivation and cell transforming abilities of large Mafs to examine the possible relationship between transactivation and cell transformation. One of these Maf proteins, MafA was less effective in transactivation than the others, but was much more efficient in cell transformation. We constructed recombinants between MafA and MafB, and found that the strong transforming and weak transactivation abilities of MafA are associated with the DNAbinding/hinge region. Mutagenesis experiments showed that phosphorylation of the amino-terminal domain of MafA has a significant effect on transactivation and cell transformation as well. We also constructed fusion proteins that include the DNA-binding domain of MafA and the hormone-binding domain of the estrogen receptor (ER). These constructs induce cell transformation in a hormone-dependent manner. The inducible Maf will provide a valuable tool in the analysis of transformation.
Results
The structure of the chicken mafA gene Clones of the chicken mafA gene were isolated by screening a chicken genomic library with a v-maf probe under relaxed hybridization conditions. We studied one of the clones, M41, by restriction mapping and nucleotide sequence analysis. Figure 1 shows the structure of the chicken mafA gene. This gene does not contain an intron as judged by comparison to previously reported chicken (Ogino and Yasuda, 1998) and Japanese quail (Benkhelifa et al., 1998) mafA cDNA. The sequence information of the chicken mafA genomic clone is available from the GenBank DNA database (Accession number of AY152408).
Transactivation and cell transforming activities of the large Maf proteins
We compared the transactivation activity of MafA, MafB and two forms of c-Maf in a luciferase reporter assay method. The two forms of c-Maf (types I and II) are generated by alternative transcriptional termination. Type I has an additional 10 amino-acid residues at its carboxy-terminus. We subcloned the coding sequences of these three genes into the pHyg-EF-2 expression vector (Nishizawa et al., 2003) . The expression plasmids for the large Maf proteins were transfected with an internal control plasmid (Renilla luciferase gene/pHyg-EF-2) and a luciferase reporter plasmid that includes a triplicated MARE (3x7/pRBGP) into chicken embryo fibroblasts (CEF). The results are summarized in Figure 2 . Type I c-Maf was the most potent activator followed by type II c-Maf and MafB. MafA was the least effective. The data suggest an apparent correlation between activity and the size of the transactivation domains (cMAF: 174aa, MafB: 129aa, MafA: 125aa). As shown below, this correlation did not hold in genetic experiments (Figure 3) .
In order to compare the cell transforming ability of the three large Maf proteins in CEF, the proteins were expressed with the avian retroviral vector, pRV-9 (Nishizawa et al., 2003) . All large Maf proteins induced cell transformation, suggesting that the structural changes seen in v-Maf are not a prerequisite of transforming ability. As we reported previously, MafB showed reduced transforming ability compared to cMaf. Although the numbers of foci formed by MafB were comparable to those by c-Maf, they were smaller and took longer to develop (Figure 3) . MafA showed the highest cell transforming ability. Focus formation was more rapid, and the saturation density of cells was highest in MafA-transformed CEF (Figure 3 ). Colony forming activities in soft agar suspension culture mirrored the focus assays. MafA was a potent inducer of anchorage-independent growth, comparable to v-Jun ( Figure 3 ). The other Maf proteins induced few and The DNA-binding domain is a major determinant of the strong cell transforming ability of MafA
In order to investigate the discrepancy between transcriptional activation and transformation in MafA, we constructed MafA/MafB chimeras ( Figure 4a ). Plasmids coding MafA-S-B and MafB-S-A, were constructed using the SacI site that is conserved in both genes. We then introduced an XhoI site at the first leucine residue of the zipper structure of MafA and MafB, without changing amino-acid sequences, and exchanged the restriction fragments to generate MafA-X-B and Maf B-X-A. Finally, we built MafA-B-A and MafB-A-B by exchanging the SacI-XhoI fragments.
These fragments contain the DNA-binding domain and hinge regions that connects to the zipper domain. We tested transactivation and cell transforming abilities after subcloning into the appropriate expression vectors.
Exchange of the N-terminal half containing the major transactivation domain (MafA-S-B and MafB-S-A in Figure 4a ) had only a minor effect on transactivation. The size of the transactivation domain does therefore not determine transactivation activity. Exchange of the zipper domain had an equally negligible effect on transactivation potential (MafA-X-B and MafB-X-A in Figure 4a ): The leucine zipper of MafB transplanted onto MafA did not enhance the transactivation potential of the hybrid, and the leucine zipper of MafA did not affect the high transactivation of MafB. However, if the SacI/XhoI fragments, containing the DNA-binding domain and hinge regions were swapped, the transactivation potentials were exchanged 
Effect of phosphorylation of MafA on its transactivation and cell transforming activities
Two serine residues in the transactivation domain of MafA are phosphorylated by ERK2 kinase in vivo, and the phosphorylation status of the two serine residues greatly upregulates transactivation activity of MafA (Benkhelifa et al., 2001) . In order to test the effect of phosphorylation on the cell transforming ability of MafA, we introduced point mutations in the phosphorylation sites. These mutants are similar to the ones of Benkhelifa et al. (2001) working with MafA of Japanese quail. They tested transactivation activity with a reporter that contains the Maf-binding A box of the quail retina-specific QR1 gene. The A box element is similar to a half site of the palindromic MARE sequence and is recognized by Maf proteins, probably at reduced efficiency. We used a triplicated palindromic MARE sequence as binding site of the reporter plasmid to achieve higher efficiency of binding. Mutation of Ser 14 slightly reduced transactivation activity of MafA (Figure 7a ). If both Ser 14 and Ser 65 were converted to alanine (MafA S14AS65A), transactivation was nearly abolished. The single mutation of Ser 65 (MafA S65A) unexpectedly increased transactivation activity.
The mutated genes were introduced into the pRV-9 retroviral expression vector, and recombinant viruses were recovered after DNA transfection into CEF. The recovered viruses were then used for infection of CEF to 
Construction of an inducible cell transformation system
To take advantage of the strong transforming ability of MafA, we designed an inducible cell transformation system. We constructed several fusion proteins that include the DNA-binding domain of MafA and the hormone-binding domain of the human ER (Kumar et al., 1986) . We have found that v-Maf and MafA with the zipper domain replaced by the yeast GCN4 retain transforming ability (Kataoka et al., 2001; Nishizawa, 2002, unpublished observation) . We used the MafA-GCN4 chimera for the ER fusions because the GCN4 zipper domain only homodimerizes, eliminating potentially complicating interactions with other bZip proteins. We also deleted the amino-terminal domain of MafA and replaced it with the nonconditional transactivation domain of the herpes simplex virus activator VP16 or with the estrogen-regulatable transactivation domain of ER. This exchange eliminates the effect of protein kinases and protein phosphatases that regulate the MafA-transactivation domain. These fusion constructs were expressed in CEF using the retrovirus vector, pRV-9. The infected cells were treated with b-estradiol or with a homologue of estrogen, 4-hydroxytamoxifen (4-HT). The hormone-binding domain of ER regulates cellular localization of the chimeric molecule and provides an estrogen-dependent transactivation activity. 4-HT also induces nuclear localization but is defective in the induction of the transactivation function of the hormone-binding domain. Two of the ER fusions, NDMafA-GCN4-ER and VP16-NDMafA-GCN4-ER induced cell transformation in a b-estradiol-dependent manner. The latter construct was particularly tight, it induced transformation only in the presence of b-estradiol. Although this construct contains the nonconditional VP16 transactivation domain, treatment with 4-HT did not induce cell transformation, suggesting dependence on the transactivation activity of the ER hormone-binding domain.
Discussion
Proto-oncogenes often require structural changes to acquire cell transforming ability. An example is the vJun protein whose high oncogenic activity results from changes in its primary structure (Bos et al., 1990) . In this study, we investigated the transforming ability of the large Maf proteins. Expression profiles and functional properties of these proteins indicate that they are regulators of tissue specific gene expression and differentiation. Yet all large cellular Maf proteins rapidly induce transformation of CEF without structural changes probably because the expression by the pRV-9 retroviral vector in CEF is both ectopic and excessive.
In chicken neuroretina cells, expression of MafA by a retroviral expression vector induces differentiation into lens cells (Ogino and Yasuda, 1998) , in contrast to the clear oncogenic effect of similarly expressed MafA in CEF. It will be interesting to determine the mechanism that governs the choice between terminal differentiation and unregulated growth.
We have previously constructed a series of deletion mutants of v-Maf, and found that there is a correlation between transactivation and transformation . However, this correlation does not hold if we compare the large Maf proteins with each other. MafA is a weak transactivator, but a potent transformer. In chimeric constructs between MafA and MafB, we identified the DNA-binding and hinge regions as the domain responsible for low transactivation and high transformation. A possible explanation for the transforming activity of MafA could be greatly elevated expression relative to MafB. We could not rule out this possibility by Western blot analysis because of the lack of antibodies that recognize these proteins and their chimeras with equal efficiency. However, the Maf B-A-B chimera differs from MafB in only five amino acids; the two proteins show different levels of transactivation and transformation, and they are translated in vitro with (Figure 6b ). MafA and MafA-B-A are also likely to be expressed at similar levels, but are different in their biological activities. Among the five amino-acid differences within the short region of MafA and MafB, two are located in hinge region that connects the DNA-interacting surface and the leucine zipper (Figure 4b ). The differences in the hinge region are reminiscent of a v-Maf mutant, Q5H, that show higher transforming ability than v-Maf . In this mutant, Gln 297 of the hinge region is replaced by His. This mutation does not affect on transactivation potential of v-Maf.
Since DNA binding of MafA and MafB are not significantly different, some other function must account for the differences in transformation and transactivation. One possibility is differential interaction with an inhibitor or activator. We recently reported that a set of Hox proteins can interact with the DNA-binding domain of c-Maf and inhibit its activity. In the case of MafA and MafB, the unknown partner would have to affect transactivation and transformation without altering DNA binding. Another possible explanation for the discrepancy between transactivation and transformation in MafA and MafB may be provided by the reporter assays. MafA may recognize and strongly activate transformation-relevant promoters, while showing weak activity with standard reporter constructs. Reporter assays probably do not accurately reflect transformation-relevant transcriptional regulation. If MafA specifically activates targets relevant for cell transformation and affects other target genes only minimally, screens for differential gene expression in MafA transformed cells would show reduced noise from irrelevant genes. Such screens could also identify variant promoter sequences that respond preferentially to transforming Maf. Incorporation of such sequences into reporter constructs would allow a better comparison between transactivation and transformation.
The importance of the transactivation function of Maf proteins is strengthened by studies of the transactivation domain. A deletion of the transactivation domain from MafA resulted in a nontransforming construct (Nishizawa, 2001, unpublished observation) , suggesting that transactivation is important for oncogenicity. Further, transactivation by MafA is stimulated by phosphorylation, and mutation of both phosphorylation sites negatively affects both transactivation and transformation. Unexpectedly, a single site mutation, S65A, enhanced both transactivation and transformation. This seemingly contradictory observation underlines the inadequacy of our current understanding of transactivation and its relationship to transformation. Replacement of the MafA transactivation domain with that of the herpes simplex virus protein VP16 greatly enhances both transactivation and transformation activities of the proteins (Nishizawa, 2001, unpublished observation) . If phosphorylation of the conserved serine residues also regulates activities of other large Maf proteins, the kinase responsible for Maf phosphorylation could be a promising target of novel anticancer drugs effective in human multiple myeloma with rearranged c-maf or mafB Sebolt-Leopold (2000) . However, preliminary results show that mutation of the conserved phosphorylation sites of human c-Maf do not affect transforming ability in CEF (Nishizawa, 2002, unpublished observation) .
The hormone-regulatable MafA fusions may become a valuable tool in target identification. This kind of conditional transcription factor can become active in the presence of an inhibitor of protein synthesis, cycloheximide, allowing the distinction between direct and indirect targets (Kruse et al., 1997) . It is best used in conjunction with other transforming constructs that address the same DNA target sequence. Candidate target genes may then be sought among the differentially expressed genes that are affected by all of these transforming constructs. We have followed this reasoning in a recent study that describes transforming hybrids containing sequences from GCN4 and VP16 (Nishizawa et al., 2003) . This combinatorial use of different regulatable constructs with identical or near-identical DNA targets could be useful in focusing on transformation-relevant genes.
Materials and methods

Molecular cloning and plasmid construction
A chicken genomic DNA library was purchased from Clontech. Genomic clones of the mafA gene were isolated by screening the library with a 0.74-kb v-maf specific probe excised from the pSae-2 plasmid (Fujiwara et al., 1993) under low stringency conditions. The insert of one of the genomic clones, lM41 was subcloned into a plasmid vector and was mapped by restriction endonucleases and sequenced. The whole coding sequences of mafA, mafB and two forms of c-maf genes were subcloned into two expression vectors, pRV-9 and pHyg-EF-2 (Nishizawa et al., 2003) . The pRV-9 is an avian retroviral vector derived from RCAS (Hughes et al., 1987; Nishizawa et al., 2003) , and subclones of this vector were used to recover recombinant viruses which express the Maf proteins, The pHyg-EF-2 vector contains the strong promoter of human elongation factor-1a gene (Mizushima and Nagata, 1990) , and the subclones in this vector were used for transient transfection assays. In order to improve expression efficiency, we replaced sequences just before the initiator methionine codon with the 5 0 -noncoding sequence of v-src gene.
Transient transfection assays
Transactivation was measured with a reporter plasmid that contained three copies of the MARE sequence upstream of the minimal promoter of rabbit b-globin gene. The MARE sequence used in the reporter was TGCTTACTAAGCA. This sequence is a variant of the consensus sequence (TGCTGACT-CAGCA), it is efficiently recognized by Maf but, unlike the consensus sequence, it is not recognized by AP-1 thus eliminating AP-1 background activity (Kataoka et al., 1994b) . Transfection and measurement of luciferase activities were performed as described previously using Lipofectamine Plus transfection reagent (Invitrogen, Carlsbad, CA, USA) and Dual-luciferase reporter assay system (Promega, Madison, WI, USA).
Cells and viruses
Primary CEF cultures were prepared from embryos supplied by SPAFAS (Preston, CT, USA) and were maintained as described previously (Vogt, 1969) . For recovery of infectious viruses, pRV-9 and its derived constructs were transfected into CEF by the DMSO transfection method (Kawai and Nishizawa, 1984) .
